Saccharomyces Boulardii on the quality of life of patients with drug resistant epilepsy

The effect of the probiotic Saccharomyces Boulardii on the quality of life of patients with drug resistant epilepsy: A randomized double-blind study

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20260315068994N1

Enrollment

Registered

2026-05-03

Start date

2026-05-22

Completion date

Unknown

Last updated

2026-06-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Drug_resistant epilepsy. Epilepsy and recurrent seizures

Interventions

Intervention 1: Intervention group: will receive one Dailyeast capsule containing the active ingredient, daily for a duration of four months. Intervention 2: Control group (placebo): will receive one

Eligibility

Sex/Gender

All

Age

14 Years to 55 Years

Inclusion criteria

Inclusion criteria: Diagnosis of drug-resistant epilepsy At least one seizure episode within the three months prior to study initiation

Exclusion criteria

Exclusion criteria: Absence of metabolic diseases, progressive neurological disorders, and hepatic, renal, gastrointestinal, or infectious conditions. Hospitalization and/or changes in concurrent medicatins, such as antibiotics, other probiotics, ect. Patients in whom medication use results in prolonged constipation or diarrhea. Patients who do not provide informed consent to participate in the clinical trial.

Design outcomes

Primary

Measure	Time frame
Depression mood change scores measured by the Beck Questionnaire. Timepoint: before the start of the study, immediately after the completion of the treatment period, and three months post-treatment. Method of measurement: Beck Depression Inventory (BDI).;Anxiety mood change scores measured by the Beck Questionnaire. Timepoint: before the start of the study, immediately after the completion of the treatment period, and three months post-treatment. Method of measurement: Beck Depression Inventory (BDI).;Percentage improvement in quality of life. Timepoint: before the start of the study, immediately after the completion of the treatment period, and three months post-treatment. Method of measurement: Quality of Life in Epilepsy Inventory (QOLIE-31).;Cognitive change scores. Timepoint: before the start of the study, immediately after the completion of the treatment period, and three months post-treatment. Method of measurement: Trial Making Test.	—

Measure

Time frame

Depression mood change scores measured by the Beck Questionnaire. Timepoint: before the start of the study, immediately after the completion of the treatment period, and three months post-treatment. Method of measurement: Beck Depression Inventory (BDI).;Anxiety mood change scores measured by the Beck Questionnaire. Timepoint: before the start of the study, immediately after the completion of the treatment period, and three months post-treatment. Method of measurement: Beck Depression Inventory (BDI).;Percentage improvement in quality of life. Timepoint: before the start of the study, immediately after the completion of the treatment period, and three months post-treatment. Method of measurement: Quality of Life in Epilepsy Inventory (QOLIE-31).;Cognitive change scores. Timepoint: before the start of the study, immediately after the completion of the treatment period, and three months post-treatment. Method of measurement: Trial Making Test.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMohabbat Fakharzadeh

Ahvaz University of Medical Sciences

Fakharzade.mhbt@gmail.com+98 912 003 9346

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Jun 11, 2026